REG - UPL Limited - Allotment of Rights Equity Shares,kept in abeyance

UPLAnnouncement

17/01/2025 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250117:nRSQ8133Ta&default-theme=true

RNS Number : 8133T  UPL Limited  17 January 2025

UPL LIMITED

 

 

 

Sub: Allotment of Rights Equity Shares, kept in abeyance

 

We refer to our disclosure dated 20(th) December 2024, wherein the Company had
allotted 9,37,92,629 Rights Equity Shares against issuance of 9,38,25,955
Rights Equity Shares to eligible equity shareholders. Further, 33,326 Rights
Equity Shares were kept in abeyance pending regulatory/other clearances.

 

In this regard, we wish to inform you that Rights Issue Committee of the Board
of Directors of the Company vide its resolution passed on 17(th) January 2025
has approved the allotment of 33,326 Rights Equity Shares of ₹ 360 per
equity share (including a premium of ₹ 358 per equity share) of which ₹ 90
per equity share (i.e. ₹ 0.50 has been paid-up as share application money
and ₹ 89.50 as a premium per equity share) has been paid on application
("Allotment") and the balance amount shall be payable on one or more
additional calls with terms and conditions such as the number of calls and the
timing and quantum of each call as may be decided by the Board / Rights Issue
Committee from time to time. The allotment has been made to eligible
applicants in compliance with order passed by the Hon'ble Special Court
constituted under the Special Court (Trial of Offences Relating to
Transactions in Securities) Act, 1992.

 

Links:

 

https://www.bseindia.com/xml-data/corpfiling/AttachLive/6e91f864-e571-4b52-b899-bf9d4268eaa0.pdf
(https://www.bseindia.com/xml-data/corpfiling/AttachLive/6e91f864-e571-4b52-b899-bf9d4268eaa0.pdf)

 

We request you to take note of the same.

 

Thanking you,

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CIRUBOURVUUAAAR